VRTX: $10B acquisition adds two leading endocrine assets, driving growth and portfolio diversification
The acquisition brings two best-in-class endocrine assets with blockbuster potential, expanding the acquirer's portfolio and supporting sustained revenue growth. The $10B deal is expected to close in Q3 2026, with strong physician support and significant synergies anticipated.Based on Vertex Pharma…